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Abstract
Developmental delay and/or intellectual disability (DD/ID) affects 1–3% of all children. At least half of these are thought to
have a genetic etiology. Recent studies have shown that massively parallel sequencing (MPS) using a targeted gene panel is
particularly suited for diagnostic testing for genetically heterogeneous conditions. We report on our experiences with using
massively parallel sequencing of a targeted gene panel of 355 genes for investigating the genetic etiology of eight patients
with a wide range of phenotypes including DD/ID, congenital anomalies and/or autism spectrum disorder. Targeted
sequence enrichment was performed using the Agilent SureSelect Target Enrichment Kit and sequenced on the Illumina
HiSeq2000 using paired-end reads. For all eight patients, 81–84% of the targeted regions achieved read depths of at least
206, with average read depths overlapping targets ranging from 3226 to 7986. Causative variants were successfully
identified in two of the eight patients: a nonsense mutation in the ATRX gene and a canonical splice site mutation in the
L1CAM gene. In a third patient, a canonical splice site variant in the USP9X gene could likely explain all or some of her clinical
phenotypes. These results confirm the value of targeted MPS for investigating DD/ID in children for diagnostic purposes.
However, targeted gene MPS was less likely to provide a genetic diagnosis for children whose phenotype includes autism.
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Introduction
Developmental delay and/or intellectual disability (DD/ID)
affects 1–3% of all children and at least half of these are thought to
have a genetic etiology. The genetic causes include microscopically
visible chromosomal imbalances, copy number variants as well as
point mutations. However, the genetic etiology remains unknown
for at least 50% of all cases of DD/ID [1]. Diagnosis of DD/ID is
challenging due to the broad spectrum of phenotypic presenta-
tions, as patients with DD/ID often have congenital anomalies
and/or autism spectrum disorders. With the advent of massively
parallel sequencing (MPS) or next generation sequencing (NGS),
there has been expectation of an increased detection of the genetic
causes of DD/ID. In particular, exome sequencing has been
identified as an effective tool for discovery of new disease genes.
However, many technical challenges remain including the uneven
depth of coverage across the exome, gaps in coverage and
mapping problems. In addition, there is the challenge of
interpreting the clinical significance of the thousands of variants
generated by exome sequencing.
An alternative approach is to perform MPS with a targeted gene
panel. Studies using panels of targeted genes have been reported
for various disease entities like cardiomyopathies [2], hearing loss
[3], epilepsy [4] and retinal disorders [5]. These studies have
shown that targeted MPS is particularly suited for clinical
diagnostic testing for genetically heterogeneous conditions where
there are a large number of known candidate genes.
We describe our experiences with using massively parallel
sequencing of a targeted gene panel of 355 genes for investigating
the genetic etiology of eight patients with a range of phenotypes
including DD/ID, congenital anomalies and autism spectrum
disorder.
Materials and Methods
Ethics Statement
This study is approved by the Institutional Review Board of KK
Women’s and Children’s Hospital and SingHealth Centralised
Institutional Review Board A. The patients were recruited with
written informed parental consent by the Genetics Service, KK
Women’s & Children’s Hospital, Singapore.
Patient phenotypes
Eight patients with phenotypes ranging from developmental
delay, multiple congenital anomalies and/or autism spectrum
disorders were selected for the targeted sequencing (Table 1). Prior
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genetic tests were normal and array comparative genomic
hybridization did not detect any copy number changes associated
with known microdeletion and microduplication syndromes.
DNA extraction
Genomic DNA was isolated from peripheral blood using the
Gentra Puregene blood kit (Qiagen Inc.,USA) according to the
manufacturer’s instructions.
Targeted gene panel and MPS
A total of 355 genes were targeted for capture and deep
sequencing. They include candidate genes associated with DD/
ID, microdeletion/microduplication syndromes, congenital anom-
alies, and autism spectrum disorders (Table S1). Using the eArray
system (Agilent Technologies Inc. USA), the capture was designed
to include exons with at least 30 bp of the flanking intronic
sequence. In addition, 5 kb of the flanking sequence in the 59UTR
and 39UTR regions were added to the targeted regions. A total of
4150 regions from the 355 genes were targeted for a final capture
size of 4.79 Mb.
Targeted sequence enrichment was performed using the Agilent
SureSelect Target Enrichment Kit (Agilent Technologies Inc.
USA). Genomic DNA was sheared using a Covaris S1 Ultra-
sonicator (Covaris, MA). Adaptor-ligated libraries were construct-
ed using Paired-End Genomic DNA kits (Illumina, CA). The
multiplexed samples were sequenced on the Illumina Hiseq
platform using 76-bp paired-end reads.
Variant analysis and prioritization
Sequencing data were aligned to hg19 using the Burrows-
Wheeler Aligner (BWA) software. PCR duplicates were removed
with the ‘samtools’ software, and variants called using the Genome
Analysis Toolkit (GATK, version 1.0) software from the Broad
Institute.
Variants were annotated based on CCDS, Refseq and Ensembl
gene transcripts. Identified variants that are listed in the NCBI
dbSNP (version 132) were filtered out, along with variants that had
poor depth or low average base quality scores. Prioritization of
variants was carried out by the following criteria: selection of
candidate genes based on patient’s phenotype, severity of the
predicted impact on gene function, conservation of amino acid
affected, and frequency of the variant in the literature and
databases including the Human Gene Mutation Database
(HGMD http://www.biobase-international.com/), Leiden Open
Variation Databases (LOVD http://www.lovd.nl/3.0/home),
Exome Variant Server (EVS, http://evs.gs.washington.edu/
EVS/) and 1000 genomes database (http://browser.http://
browser.1000genomes.org/index.html). PolyPhen-2 (http://
genetics.bwh.harvard.edu/pph2/) and SIFT (http://sift.bii.a-star.
edu.sg/) were used to predict the pathogenicity of non-synony-
mous variants. The candidate variants were confirmed by Sanger
sequencing and familial segregation testing was performed
whenever possible. The workflow is summarized in Figure 1.
Genotype data has been deposited at the European Genome-
phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is
hosted by the EBI, under accession number EGAS00001000683.
Sanger Dideoxy Terminator Sequencing
Selected variants were confirmed by Sanger dideoxy terminator
sequencing. Primers were designed with Primer3 software. PCR
was carried out with HotStarTaq PCR kit (Qiagen Inc.,USA) and
GC-Rich PCR kit (Roche Diagnostics GmbH, Mannheim,
Germany) was used for GC rich regions. Sequencing products
were resolved on an ABI3730 capillary sequencing instrument
(Applied Biosystems) and chromatograms were analysed with
Mutation Surveyor version 3.3 (SoftGenetics, LLC, State College,
PA, USA).
RNA extraction and cDNA sequencing
RNA was extracted from freshly collected whole blood using the
NucleoSpin RNA blood kit (Machery-Nagel GmbH, Germany)
and cDNA was synthesized using the Qiagen OneStep RT-PCR
kit (Qiagen Inc., USA). PCR primers were designed within exons
and PCR was performed using cDNA as template. PCR products
were visualised on gels and sequenced as described above.
Table 1. Phenotypes and genetic testing of the eight patients.
Patient Age Gender Phenotypes Previous genetic testing
Patient 1 11 Male DD/ID, hydrocephalus, adducted thumbs, agenesis of corpus callosum, spasticity, optic atrophy,
CTEV, no speech
Karyotype, aCGH
Patient 2 4 Male DD, microcephaly, dysmorphism (hypertelorism, low set ears, posteriorly rotated, microstomia with
tented upper lip, high forehead with cowlick), hypotonia, short fingers, bilateral CTEV, bifid scrotum,
undescended testes, speech delay, family history of neurodevelopmental disorders and early deaths
aCGH
Patient 3 4 Female Dandy-Walker malformation, bilateral post-axial polydactyly, ventricular septal defect; anal stenosis,
hearing loss, omphalocoele minor, hypoplastic nipple, sacral dimple, low set ears, deep set eyes,
significant tendency to keloid formation
Karyotype, fluorescent in-situ
hybridization for 6p deletion,
aCGH
Patient 4 11 Female DD, autism spectrum disorder diagnosed at age 3K. Karyotype, Angelman
Syndrome, aCGH
Patient 5 5 Male DD, no speech, no eye contact Karyotype, FragX, aCGH
Patient 6 5 Male Speech delay, autism spectrum disorder, sister with DD and Turner’s syndrome Karyotype, FragX, aCGH
Patient 7 11 Male Normal IQ, mild autism, does not interact with peers, hyperactive Karyotype, aCGH
Patient 8 7 Female DD, intellectual disability? autism spectrum disorder, speech delay, moderate IQ, hypertelorism,
depressed nasal bridge, prominent jaw, brother with ADHD
Karyotype, FragX, aCGH,
DD = developmental delay; ID = intellectual disability; CTEV = congenital talipes equinovarus; ADHD = attention deficit hyperactivity disorder; aCGH = array
comparative genomic hybridization; FragX = Fragile X
doi:10.1371/journal.pone.0093409.t001
Targeted Gene Panel for Intellectual Disability
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Results
Data output and quality
For all eight patients, 81–84% of the targeted regions achieved
read depths of at least 206, with average read depths overlapping
targets ranging from 3226 to 7986 (Table 2). There were a few
genes with very poor coverage. In particular, coverage of IKBKG,
CFC1 and GTF21 was generally poor. In addition, read depths
were ,106 for a few exons in genes like ARX, SHANK3, MECP2,
SALL1, TBX1, PGA5, NF1, CHRNA7, NIPA1, DMD. These were
usually either in exon 1 or within GC rich regions.
Variant detection and prioritization
After filtering out the common variants present in dbSNP and
variants with MAF .1% in EVS and the 1000 Genome browser,
1505 single nucleotide variants (SNVs) were identified in the eight
patients, with a range of 131 to 236 SNVs per patient. A small
number of variants were selected for validation by Sanger
sequencing based on the prioritization criteria shown in Figure 1.
Patient 1
A total of 172 SNVs were detected in Patient 1 who is male with
a 46,XY karyotype. Of the SNVs affecting exons, the top
candidate mutation was a putative splice site mutation in the
L1CAM gene, c.3458-1G.A, located at chrX: 153129005 (hg19)
which was sequenced at 886 (Figure 2A). This variant was
confirmed by Sanger sequencing (Figure 2B) and parental testing
confirmed that the hemizygous mutation was inherited from his
healthy mother. The variant affects the invariant AG acceptor
splice site of intron 25 and is predicted to affect the splicing of exon
26. cDNA sequencing confirmed that splicing is affected at exon
26 and that the variant results in a deletion of 5 bp
(r.3458_3462delTGAAG) from exon 26,which causes a frame
shift and a premature stop leading to a predicted truncated protein
of 1153 amino acids (Figure 2C).
Patient 2
Patient 2 is male with a 46,XY karyotype. Among the 129 SNVs
detected in this patient, the top candidate was a c.7156C.T
Figure 1. Variant analysis and prioritization workflow. Summary of our variant evaluation process for identifying candidate mutations
doi:10.1371/journal.pone.0093409.g001
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(p.R2386X) mutation in the ATRX gene, located at chr X:
76776310 (Figure 3A). The mutation was validated by Sanger
sequencing (Figure 3B), and extended family testing showed that
the mutation was present in the unaffected mother and in an
affected brother (Figure 3C), but was absent in the father and
unaffected sister.
Patient 3
A total of 236 SNVs were detected in Patient 3, who is female
with a 46,XX karyotype. The top candidate SNVs included
potential splice site SNVs in USP9X and FGFR2, and non-
synonymous variants in RELN, DMD,MAP7D2 and ZNF41. Indels
in exonic regions of SHROOM4, ZIC2 and MED12 were also
investigated. All the SNVs and indels were confirmed by Sanger
sequencing and parental testing showed that all the variants were
inherited except for the USP9X splice site variant. The de novo
c.1986-1G.T variant in USP9X (chrX: 41025124) is the likely
causative mutation (Figure 4A & 4B). This variant is novel and is
predicted to affect the acceptor splice site of intron 15 of the
USP9X gene. cDNA sequencing with primers in exon 13 and exon
17 showed the normal transcript together with the low-level
presence of an altered transcript. The altered transcript showed a
deletion of 13 bases (r.1986_1998delATTTTTATTGAAG) which
is predicted to result in an altered protein and a premature stop
codon p.F663Mfs*18 (Figure 4C & 4E). A second, independent
pair of primers in exons 13 and 16 also showed the presence of this
low-level altered transcript. Sequencing of the RT-PCR product
from a control RNA only showed the presence of the normal
transcript with no altered transcript seen (Figure 4D)
Patients 4–8
The top candidate variants of patients 4–8 are listed in Table 3.
All these variants have been confirmed by Sanger sequencing and
their inheritance was tested if parental samples were available. In
addition to the variants detected by MPS, previous array CGH
using Affymetrix SNP6 for Patient 5 showed a 134 kb deletion at
9p21.1 extending from 28,609,725–28,743,782 (hg19) involving
the LINGO2 gene (data not shown). This copy number change was
initially thought to have no clinical significance.
Discussion
The average read depths achieved for the targeted regions were
very high (.3226) and read depths of .206 were achieved for
81–84% of the targets. There was some variation in coverage, with
overall poor coverage for just three genes and poor coverage in a
few exons for another 10 genes.
Targeted MPS detected the causative mutations in L1CAM in
Patient 1 and ATRX in Patient 2, which were consistent with their
respective phenotypes. In Patient 1 the c.3458-1G.A mutation in
the L1CAM gene affected the splicing process and cDNA
sequencing confirmed the presence of a truncated transcript.
Mutations in the L1CAM gene are associated with L1 syndrome,
an X-linked recessive disorder. The major features of L1 syndrome
include congenital hydrocephalus, adducted thumbs, spastic
paraplegia, agenesis of the corpus callosum and cognitive
impairment [6]. These features were all present in Patient 1.
The c.3458-1G.A mutation in Patient 1 is novel but a splice site
mutation at the same position (c.3458-1G.C) has been reported
in a male with L1 syndrome [7].
In Patient 2, a p.R2386X mutation in the ATRX gene
segregated with the clinical phenotypes in the family. Mutations
in ATRX cause X-linked alpha thalassaemia mental retardation
(ATR-X syndrome) in males, which is associated with profound
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developmental delay, facial dysmorphism, genital abnormalities
and alpha thalassemia [8]. The features in Patient 2 were largely
consistent with ATR-X syndrome. The p.R2386X mutation
occurs in exon 34 of the ATRX protein. This mutation has been
reported in three separate instances in the literature and all cases
have involved severe mental retardation and genital abnormalities
[9]. Independent testing of this family by conventional ATRX
molecular testing corroborated our MPS result [10].
Patient 3 has multiple congenital anomalies. A de novo
c.1986G.T mutation in the USP9X gene is likely to be causative
for all or some of her clinical phenotypes. We showed the presence
of a truncated cDNA sequence which is predicted to result in a
truncated protein. It is possible that the truncated protein might
have a dominant negative effect or impaired protein function.
USP9X is a member of the USP family of deubiquinating enzymes
(DUBs) which process ubiquitin precursors and ubiquinated
proteins. It has an important regulatory role in protein turnover
and is an essential component of the TGFb/BMP signalling
cascade through its control of SMAD4 monoubiquitination [11].
The drosophila homolog (FAF) is essential for normal eye
development and embryonic viability and the mouse homolog
(FAM) has been shown to play essential roles in embryonic
development [12–14]. There has been one published report of a
truncating mutation in USP9X which segregated with disease in an
X-linked mental retardation family [15]. Identification of more
patients with mutations in the USP9X gene will be needed to
confirm the association with ID and congenital anomalies.
Patients 4, 5, 6, 7, 8 have phenotypes that included autism
spectrum disorders. Autism spectrum disorders are complex
disorders. Despite the compelling argument for a genetic basis
for autism, it is estimated that a specific genetic cause has been
established for only 15% of cases [16]. Recent large exome studies
in trios have implicated a number of genes, but did not identify
any gene as a major cause of autism [17–19]. The exome studies
all showed the extreme heterogeneous nature of autism and also
indicated that many of the genes implicated were interconnected
by shared pathways. The exome trio studies also showed the
importance of de novo point mutations in autism.
Single variants in a number of genes were detected but variants
in AHI1 and MAP7D3 were seen in Patient 5 and Patient 7. AHI1
Figure 2. L1CAM splice site mutation in Patient 1. (A) IGV snapshot of c.3458-1G.A variant in the L1CAM gene (Chr X:153129005, hg19). (B)
Sanger sequencing confirmation of c.3458-1G.A variant (NM_000425.3) (C) Partial cDNA sequence showing the mutant allele with the 5 bp deletion.
doi:10.1371/journal.pone.0093409.g002
Targeted Gene Panel for Intellectual Disability
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is highly expressed in fetal brain and also in the cerebellum and
cerebral cortex of the adult brain, and mutations in AHI1 cause
Joubert Syndrome [20]. Genetic association has also been
reported between AHI1 and autism [21]. The AHI1 variant
E1086G is a pathogenic mutation in a case of Joubert syndrome
[22]. The E1086G and D1179Y variants have been reported in
the EVS database with a frequency of 0.008% and 0.033%
respectively. MAP7D3 has not been associated with autism
spectrum disorders. There was one report of a truncating variant
in MAP7D3 in an X-linked mental retardation family that did not
segregate with disease. The T335M variant has been reported in
the EVS database with a frequency of 0.019% (2 of 10444 alleles).
Novel variants in CREBBP, TSC1 and FMR1 were detected in
Patient 4. These genes have been associated with syndromic
autism and were probably unlikely to be causative of her
phenotypes as they were inherited from her healthy parents.
Similarly there were interesting candidate variants in Patient 6 in
NIPA1 gene which has been associated with autism. Again these
variants were inherited and thus less likely to be causative of his
autism spectrum disorder.
In Patient 7, variants were found in SYNGAP1 and SEMA5A
which have been linked to autism [23]. This patient also had a
V528M variant in FLNA that has been reported in a case of
bilateral periventricular nodular heterotopia [24] and also as a
functional polymorphism [25]. Novel variants in FOXP1, ATRX,
AUTS2, CSMD1 were detected in Patient 8. All these genes have
been associated with autism and other neurodevelopmental
disorders. However, all these variants are inherited from her
healthy parents and thus their role in her phenotype remains
uncertain. In particular mutations and deletions in FOXP1 have
been shown to cause autism, mental retardation and speech and
language deficits [26,27]. The A100G variant in FOXP1 has been
predicted to be damaging by PolyPhen 2 and SIFT. The novel
V260I variant in AUTS2 is also of interest. This variant is present
only in AUTS2 isoform 3, the shortest isoform comprised of 266
amino acids. The AUTS2 gene was first identified as a candidate
gene for autism when it was shown to be disrupted by a
Figure 3. ATRX p.R2386X mutation in Patient 2. (A) IGV snapshot of c.7156C.T variant in ATRX (Chr X:76776310, hg19). (B) Sanger sequencing
confirmation of c.7156C.T (p.R2386X, NM_00489.3) in Patient 2. (C) Sanger sequencing showing heterozygous c.7156C.T variant in the mother.
doi:10.1371/journal.pone.0093409.g003
Targeted Gene Panel for Intellectual Disability
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translocation breakpoint in a pair of autistic twins [28]. Mutations
in the AUTS2 gene have also been identified in patients with
mental retardation [29].
Patient 5 also had a 134 kb deletion at 9p21.1 affecting the
59UTR and first two exons of the LINGO2 gene. This deletion was
not present in his mother and the father’s DNA was not available
for testing. Deletions affecting the LINGO2 gene have been
reported in a cohort of Utah autism patients [30]. There is a
possibility that the 9p21.1 deletion could act in conjunction with
other SNVs in Patient 5 to influence his phenotype. Recent
publications have highlighted the potential effects of polygenic
mutational events, variable expressivity, variable penetrance, and
CNV burden on complex disorders like autism [31–34]. All these
factors complicate the diagnosis of the causes of autism spectrum
disorders. The unavailability of some parental samples and the
lack of complete phenotyping of parents in our study also limit the
ability to predict the causality of some of the variants detected.
Despite the progress in genetic testing, 50–60% of the causes of
DD/ID remain unknown. This is unfortunate as a clinical
diagnosis of DD/ID provides crucial information for diagnostics
and helps in understanding the mechanisms of the disease
including the options for management and treatment. In addition,
it puts an end to the testing odyssey and gives families closure and
may also be important for future reproductive decisions.
This pilot study has confirmed the value of targeted MPS for
investigating DD/ID and multiple congenital anomalies in
children for diagnostic purposes. Causative mutations were found
in two of the eight patients tested and a likely causal mutation was
found in another patient. For the other five patients, no
conclusions can be made about the variants as no compelling de
novo variants were found. Thus, targeted gene MPS was less likely
to provide a genetic diagnosis for children whose phenotype
includes autism.
The advantages of targeted gene sequencing as opposed to
whole exome sequencing is the increase in numbers of patients
who could be sequenced and hence an increase in the number of
patients who might receive a diagnosis. With targeted gene
sequencing a greater depth of coverage could be achieved at a
lower cost. The increased depth will facilitate the detection of
indels that might be missed by exome sequencing. Targeted
sequencing also obviates the problem of incidental results. Clinical
interpretation of novel variants remains challenging but should
gradually become easier with the continued development of
variant databases of healthy controls as well as locus-specific
disease databases.
Figure 4. USP9X splice site mutation in Patient 3. (A) IGV snapshot of c.1986-1G.T variant in USP9X (Chr X:41025124, hg19). (B) Sanger
sequencing confirmation of c.1986-1G.T variant (NM_001039590.2) in Patient 3. (C) Partial cDNA sequence showing expression of both the wild type
and low level mutant allele with the 13 bp deletion. (D) Partial cDNA sequence of control patient. (E) Partial genomic DNA sequence of exon 15
(uppercase, blue) and intron 14 (lowercase, red) of USP9X gene showing the c.1986-1G.T variant (arrow) and the 13 bp deletion
(r.1986_1998delATTTTTATTGAAG) which is underlined.
doi:10.1371/journal.pone.0093409.g004
Targeted Gene Panel for Intellectual Disability
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